Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
24.80
-0.15 (-0.60%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Revenue
In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%. Arcus Biosciences had revenue of $33.00M in the quarter ending December 31, 2025, with 26.92% growth.
Revenue (ttm)
$247.00M
Revenue Growth
-4.26%
P/S Ratio
12.61
Revenue / Employee
$410,982
Employees
601
Market Cap
3.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 588.99M |
| Arcutis Biotherapeutics | 376.07M |
| Nektar Therapeutics | 55.23M |
| Alumis | 24.05M |
| NewAmsterdam Pharma Company | 22.50M |
| Relay Therapeutics | 15.36M |
RCUS News
- 4 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 days ago - What's Going On With Arcus Biosciences Stock On Wednesday? - Benzinga
- 7 days ago - Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates - Business Wire
- 7 weeks ago - Arcus Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 2 months ago - Arcus Biosciences Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 2 months ago - Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer - Business Wire